Focused On-demand Library for Chromodomain-helicase-DNA-binding protein 1-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86WJ1

UPID:

CHD1L_HUMAN

Alternative names:

Amplified in liver cancer protein 1

Alternative UPACC:

Q86WJ1; A5YM64; B4DDE1; B5MDZ7; Q53EZ3; Q5VXX7; Q6DD94; Q6PK83; Q86XH3; Q96HF7; Q96SP3; Q9BVJ1; Q9NVV8

Background:

Chromodomain-helicase-DNA-binding protein 1-like, also known as Amplified in liver cancer protein 1, plays a crucial role in DNA repair. It acts as an ATP-dependent chromatin remodeler, facilitating chromatin restructuring post-DNA damage. This protein is adept at recognizing and binding to poly-ADP-ribosylated histones, a key step in the DNA damage response, thereby activating its chromatin remodeler activity to promote efficient DNA repair.

Therapeutic significance:

Understanding the role of Chromodomain-helicase-DNA-binding protein 1-like could open doors to potential therapeutic strategies. Its pivotal function in DNA repair mechanisms positions it as a target for developing treatments aimed at enhancing the DNA damage response in diseases characterized by genomic instability.